



SPAFID  
CONNECT

Informazione Regolamentata n. 20106-6-2021	Data/Ora Ricezione 08 Marzo 2021 19:14:25	MTA - Star
--	---	------------

Societa' : Pharmanutra S.p.A.  
Identificativo : 143243  
Informazione  
Regolamentata  
Nome utilizzatore : PHARMANUTRAN02 - Lacorte Roberto  
Tipologia : REGEM  
Data/Ora Ricezione : 08 Marzo 2021 19:14:25  
Data/Ora Inizio : 08 Marzo 2021 19:14:26  
Diffusione presunta  
Oggetto : PR PHN - Modification corporate events  
2021

*Testo del comunicato*

Vedi allegato.

## PHARMANUTRA S.P.A.: MODIFICATION OF THE 2021 CORPORATE EVENTS CALENDAR

Pisa, 8<sup>TH</sup> March 2021 – [PharmaNutra S.p.A.](#) (the “Company”) announces that, pursuant to Article 2.6.2 of the Rules of the Markets organised and managed by Borsa Italiana, the 2021 corporate events calendar is modified as indicated in the table below. However, all the other dates are currently confirmed as per the press release issued on the 29<sup>th</sup> of January 2021.

Date	Event
March 22 <sup>nd</sup> , 2021	Board of Directors for the examination of the Financial Statements as of 31st December 2020

**PharmaNutra S.p.A.**

Founded and led by the President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003. It develops unique nutritional supplements and innovative nutritional devices, handling the entire production process, from proprietary raw materials to finished product. The effectiveness of its products is documented by considerable scientific proof. The Group distributes and sells its products in Italy and abroad. In Italy, products are sold through a network of approximately 130 Pharmaceutical Representatives serving doctors and also exclusively selling PharmaNutra products to pharmacies throughout Italy. Products are sold in 50 countries abroad, through 32 partners selected from among the finest pharmaceutical companies. Over the years, PharmaNutra has stood out in the production of iron-based nutritional supplements with the trademark SiderAL®, where it can claim important Sucrosomial Technology® patents. The Group has developed a precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence.

[PharmaNutra.it](http://PharmaNutra.it)

For further information:

**PharmaNutra S.p.A.**

Via Delle Lenze, 216/b - 56122 Pisa  
Tel. +39 050 7846500  
[investorrelation@pharmanutra.it](mailto:investorrelation@pharmanutra.it)

Internal Press Office

[press@calabughi.com](mailto:press@calabughi.com)

**Press Office - Spriano Communication & Partners**

Via Santa Radegonda, 16 - 20121 Milan  
Tel. +39 02 83635708

Matteo Russo

[mrusso@sprianocommunication.com](mailto:mrusso@sprianocommunication.com)

Cristina Tronconi

[ctronconi@sprianocommunication.com](mailto:ctronconi@sprianocommunication.com)

Fine Comunicato n.20106-6

Numero di Pagine: 4